NAV

Pranoprofen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Pranoprofen is a topical anti-inflammatory agent used for the treatment of non-infectious inflammatory conditions such as blepharitis and conjunctivitis. Pranoprofen ophthalmic solution may also be used post-operatively to manage inflammation.

Generic Name
Pranoprofen
DrugBank Accession Number
DB13514
Background

Not Available

Type
Small Molecule
Groups
Experimental, Investigational
Structure
3D
Similar Structures
Weight
Average: 255.2686
Monoisotopic: 255.089543287
Chemical Formula
C15H13NO3
Synonyms
  • Pranoprofen
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofPost operative eye inflammation•••••••••••••••••••• • •••••
Treatment ofNon-infectious eye inflammation•••••••••••••••••••• • •••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Pranoprofen.
AcemetacinThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Acemetacin.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pranoprofen.
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Pranoprofen.
AminophenazoneThe risk or severity of adverse effects can be increased when Aminophenazone is combined with Pranoprofen.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
S01BC09 — Pranoprofen
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as chromeno[2,3-b]pyridines. These are aromatic heteropolycyclic compounds containing pyridine linearly fused to the pyran moiety of a benzofuran ring system.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzopyrans
Sub Class
1-benzopyrans
Direct Parent
Chromeno[2,3-b]pyridines
Alternative Parents
Diarylethers / Pyranopyridines / Pyridines and derivatives / Benzenoids / Heteroaromatic compounds / Oxacyclic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds
show 4 more
Substituents
Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Chromeno[2,3-b]pyridine / Diaryl ether / Ether / Heteroaromatic compound
show 11 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
2R7O1ET613
CAS number
52549-17-4
InChI Key
TVQZAMVBTVNYLA-UHFFFAOYSA-N
InChI
InChI=1S/C15H13NO3/c1-9(15(17)18)10-4-5-13-12(7-10)8-11-3-2-6-16-14(11)19-13/h2-7,9H,8H2,1H3,(H,17,18)
IUPAC Name
2-{5H-chromeno[2,3-b]pyridin-7-yl}propanoic acid
SMILES
CC(C(O)=O)C1=CC2=C(OC3=C(C2)C=CC=N3)C=C1

References

General References
  1. TITCK Product Information: Oftalar (pranoprofen) ophthalmic drops [Link]
Human Metabolome Database
HMDB0041996
ChemSpider
4719
BindingDB
50286819
ChEBI
32040
ChEMBL
CHEMBL367463
Wikipedia
Pranoprofen

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4CompletedTreatmentMacular Edema1
Not AvailableCompletedTreatmentRetinal Diseases1
Not AvailableUnknown StatusNot AvailableKeratitis, Herpetic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionOphthalmic0.00100 g
Solution / dropsOphthalmic
Solution / dropsOphthalmic5 ml
Solution / dropsOphthalmic0.1 %
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.03 mg/mLALOGPS
logP2.54ALOGPS
logP2.94Chemaxon
logS-2.4ALOGPS
pKa (Strongest Acidic)3.63Chemaxon
pKa (Strongest Basic)2.24Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area59.42 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity70.02 m3·mol-1Chemaxon
Polarizability26.86 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-08fu-1890000000-06505a892e2e2aed0e0f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-1290000000-d70f1e7dd20d79171ae0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-08fr-0090000000-49d7a0b404fc7966cee7
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0ik9-0090000000-f4a76e02223c2c07f9f7
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0090000000-a3f74b0aa3902d1dfc14
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-03di-0090000000-35dbaefb9065e2340337
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-08fs-1940000000-83775005ea509acdd392
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0bu0-0970000000-1c8e3950c8067e33360d
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-170.2971661
predicted
DarkChem Lite v0.1.0
[M-H]-159.4085
predicted
DeepCCS 1.0 (2019)
[M+H]+171.1166661
predicted
DarkChem Lite v0.1.0
[M+H]+161.80391
predicted
DeepCCS 1.0 (2019)
[M+Na]+170.4297661
predicted
DarkChem Lite v0.1.0
[M+Na]+167.85995
predicted
DeepCCS 1.0 (2019)

Enzymes

Details1. Human Cyclooxygenases (Protein Group)
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Components:
NameUniProt ID
Prostaglandin G/H synthase 1P23219
Prostaglandin G/H synthase 2P35354
References
  1. Notivol R, Martinez M, Bergamini MV: Treatment of chronic nonbacterial conjunctivitis with a cyclo-oxygenase inhibitor or a corticosteroid. Pranoprofen Study Group. Am J Ophthalmol. 1994 May 15;117(5):651-6. doi: 10.1016/s0002-9394(14)70073-x. [Article]

Carriers

Details1. Serum albumin
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Regulator
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Nomura T, Sakamoto K, Imai T, Otagiri M: Study of interaction of pranoprofen with human serum albumin: binding properties of enantiomers and metabolite. J Pharmacobiodyn. 1992 Oct;15(10):589-96. doi: 10.1248/bpb1978.15.589. [Article]

Drug created at June 23, 2017 20:43 / Updated at May 15, 2021 22:41